vimarsana.com
Home
Live Updates
Grey Wolf Therapeutics Announces Dosing of First Patient in
Grey Wolf Therapeutics Announces Dosing of First Patient in
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
/PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer...
Related Keywords
Camberwell ,
Victoria ,
Australia ,
United Kingdom ,
Melbourne ,
New Zealand ,
Australian ,
Peter Joyce ,
Grey Wolf Therapeutics ,
Inhibitor Enters Clinical Development ,
Grey Wolf Therapeutics Pty Ltd ,
Centers Clinical ,
Wolf Therapeutics ,
Immunopeptide Targeting Trial ,
Grey Wolf ,
Wolf Therapeutic ,
Australian New Zealand Clinical Trial Registry ,
Strategic Partners ,